Therapeutic strategies for TEX involve reducing ROS, lowering tumor hypoxia to prevent T cell exhaustion 71, inhibiting glycolysis to enhance CD8+ TM cell function 72, and promoting FAO to regulate mitochondrial CD8+ TILs (e.g., PGC-1α agonist bezafibrate) 73. This evidence concerns the gene CD8A and neoplasm.